Neurocrine Biosciences (NBIX) EBT Margin Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EBT Margin Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.87 Bn | 624.11 Bn | 17.26 Bn | -68.00 |
| 2 | AbbVie | 440.91 Bn | 434.35 Bn | 12.70 Bn | 1,510.00 |
| 3 | Merck | 366.10 Bn | 358.96 Bn | 12.21 Bn | -3,574.00 |
| 4 | Novartis Ag | 267.00 Bn | 259.31 Bn | 11.24 Bn | -261.00 |
| 5 | Pfizer | 159.23 Bn | 147.53 Bn | 10.94 Bn | -2,512.00 |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | -504.00 |
| 7 | Revolution Medicines | 44.24 Bn | 44.24 Bn | - | - |
| 8 | Incyte | 25.34 Bn | 20.80 Bn | 1.57 Bn | -101.00 |
| 9 | United Therapeutics | 21.48 Bn | 18.82 Bn | 683.80 Mn | -356.00 |
| 10 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -629.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -629.00 |
| Mar 31, 2026 | 2,773.00 |
| Dec 31, 2025 | 382.00 |
| Sep 30, 2025 | 612.00 |
| Jun 30, 2025 | 649.00 |
| Mar 31, 2025 | -413.00 |
| Dec 31, 2024 | -1,257.00 |
| Sep 30, 2024 | 741.00 |
| Jun 30, 2024 | -1,015.00 |
| Mar 31, 2024 | 3,127.00 |
| Dec 31, 2023 | 985.00 |
| Sep 30, 2023 | -206.00 |
| Jun 30, 2023 | 3,302.00 |
| Mar 31, 2023 | -3,146.00 |
| Dec 31, 2022 | 3,304.00 |
| Sep 30, 2022 | 1,493.00 |
| Jun 30, 2022 | -2,606.00 |
| Mar 31, 2022 | -461.00 |
| Dec 31, 2021 | -2,124.00 |
| Sep 30, 2021 | 3,239.00 |